• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Chennai , Dec. 1

BIOCON'S long-term aim is to move out of making copycat drugs to discovering new drugs, the first of which is in the midst of clinical trials.

Ms Kiran Mazumdar-Shaw, Biocon's Chairman and Managing Director, said the first proprietary drug (an antibody) that could be used to combat cancer has fared well in trials.

She described the company's strategy as one of using generics (copycat drugs) in the short-term, bio-generics in the medium term, and proprietary drugs in the long term. Ms Shaw was in here in connection with the launch of the company's branded insulin, Insugen.

Biocon's manufacturing capacity for insulin at 500 kg a year is the largest of its kind in Asia. Insulin is expected to contribute a significant extent of revenue over the next few years.

More Stories on : Outlook | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Australian co wins ONGC contract for `digital oil field'

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line